Company: AZN
Filing Date: 2025-09-29
Form Type: 6-K
Source: 0001654954-25-011177
Chunk: 8

Company: ASTRAZENECA PLC
Filing Date: 2025-09-29
Form: 6-K
Chunk 8
---
249-57.

10. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 4.2025.

11. Zaborowski AM, et al. Neoadjuvant systemic therapy for breast cancer. Br J Surg . 2023;110(7):765-772.

12. Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;10.3322/caac.21834.

13. Cheng X. A comprehensive review of HER2 in cancer biology and therapeutics. Genes . 2024;15(7):903.

14. Tarantino P, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. J An Onc . 2023;34(8):645-659.

15. Ahn S, et al. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med . 2019;54(1):34-44.

16. National Cancer Institute. SEER Cancer Stat Facts: Female Breast Cancer Subtypes. Available at: https://seer.cancer.gov/statfacts/html/breast-subtypes.html. Accessed September 2025

#### Matthew Bowden

#### Company Secretary

#### AstraZeneca PLC
<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| AstraZeneca 
 PLC         |

Date:29 September 2025

| By: /s/           
 Matthew Bowden    |
| Name:             
 Matthew Bowden    |
| Title:            
 Company Secretary |